Photobiomodulation: Which Indications Hold Up

So a patient comes in with a red-light panel they bought online and wants to know what to aim it at. What's my first question back to them?

Ask what it claims to deliver in milliwatts per square centimeter at the distance you'd actually use it. That number — irradiance, power density — is almost never on the box, and without it you cannot calculate fluence, the joules-per-square-centimeter dose, which is what the trials report.

And if they don't have that number?

Then they have a light source, not a dose. That's the core problem with the commercial market.

Okay. So what does the mechanism actually say is happening?

Red and near-infrared photons — roughly 630 to 850 nanometers — are absorbed by cytochrome c oxidase, the terminal enzyme of the mitochondrial electron transport chain. The current model is that absorbed light displaces inhibitory nitric oxide from the enzyme's active site, briefly increasing electron flow and triggering a downstream redox signal.

So it's a signaling effect, not the light literally energizing the cell.

Exactly. And that predicts the dose behavior — there's a therapeutic window, not a linear ramp. Too little does nothing. Too much suppresses the same pathway. Consumer panels tend to underdose; some of the unregulated full-body beds may overdose.

What indication actually has guideline support?

Oral mucositis prevention in patients receiving head-and-neck radiation or high-dose chemotherapy before stem cell transplant. The Multinational Association of Supportive Care in Cancer, MASCC, recommends low-level laser therapy for that. That's the one place a guideline body has signed off.

What about the things longevity clinics are promoting — skin, cognition, joint pain?

Chronic musculoskeletal pain has reasonable RCT data, mostly from WALT — the World Association for Laser Therapy — reviewed trials. Effect sizes are modest, control blinding is difficult, and it's not guideline-recommended. Skin texture and collagen outcomes have industry-sponsored trial data, no independent replication at scale. Transcranial application for cognition is mechanistically interesting but the human trial evidence is early-phase and small.

So for the longevity clinic patient, what do I actually say?

Safety profile is genuinely good — low-energy, non-ionizing, no meaningful thermal risk at standard consumer irradiances. So I'm not telling them to throw it out. I'm telling them the evidence for most promoted indications is preliminary, and that the device probably isn't delivering what the trials used unless they can verify the irradiance.

Is there a way to verify it without a lab?

Affordable optical power meters exist — under a hundred dollars. Any device manufacturer unwilling to publish irradiance at specified distances is a flag.

What should I not act on — what's the overclaim I'll hear most?

Mitochondrial "recharging" as a systemic anti-aging treatment. The mechanism doesn't support systemic effect from a panel on one body surface, and there are no clinical endpoint trials in healthy aging populations. That's marketed without evidence.

Single thing to remember?

The biology is real, the one guideline indication is narrow, and the dose is almost never specified on devices patients actually buy. Irradiance at stated distance — that's the question that separates this from a decorative lamp.